Engelking seeks to balance research and medicine
When he was young, Luke Engelking’s mother asked him what he wanted to be when he grew up. His answer? “’A mad scientist,’” he said.
Engelking certainly was exposed to the idea of a career in science and medicine early, as his mother pursued a second career as a physician’s assistant during his high school years. “Unfortunately, she had a number of rare autoimmune diseases and was often in and out of doctors’ offices,” Engelking said. “From then on, I always knew I wanted to go to med school. However, I wasn’t always certain that I wanted a Ph.D.”
Engelking ended up doing both. He went to medical school at the University of Texas Southwestern Medical Center, where he got his M.D.–Ph.D. in the lab of Nobel laureates Michael Brown and Joe Goldstein, best known for their discovery of the low-density lipoprotein receptor and its regulation of cholesterol metabolism. He enjoyed working with Brown and Goldstein.
“It was a very productive time,” Engelking said. “I really didn’t appreciate working under their aegis when I was doing it. … Once you’re out on your own, everything is more of a struggle.”
Engelking has embraced that struggle. After a residency at Massachusetts General Hospital and a clinical and research fellowship back at UT Southwestern, he not only began seeing patients as an attending physician but also opened his own research lab as an assistant professor in the departments of internal medicine and molecular genetics, studying the role of sterol receptor element-binding proteins in colon cancer growth and progression.
Now an associate professor, Engelking balances his time between seeing patients and conducting research. In addition, he is working to establish a clinical research program in colon cancer genetics so data on mutations of enrolled patients can be made publicly available to researchers at UT Southwestern and around the world.
“It’s my hope that we’ll be able to synergize the clinical work with the work going on in the lab,” he said. “It’s a challenge to try to get all of this work to align — I hope I’m making progress, but we’re not quite there yet.”
Identifying markers of cancer cell proliferation in the intestine
As a physician, Luke Engelking practices adult gastroenterology, focusing on patients with inherited mutations that lead to colorectal cancers as in Lynch and familial adenomatous polyposis, or FAP, syndromes.
In the Engelking lab, research focuses on the roles of lipids in intestinal epithelial cell growth. The lab uses Cre-lox and CRISPR tools to alter gene expression, RNA-seq and lipidomics to profile cell markers, and intestinal organoids from both humans and mice as model systems.
The researchers hope that discovering novel mechanisms by which sterol receptor element-binding proteins, or SREBPs, regulate tumor cell growth and proliferation will present new drug targets for the treatment of colon cancer. Recently, the lab demonstrated that selective loss of SREBP-2, which blocks cholesterol synthesis, leads to overgrowth and increased proliferation of intestinal progenitor cells.
“What I really hope to do is move toward patient-oriented studies,” Engelking said. “Perhaps we’ll find patients with FAP phenotypes but unknown genetic markers. There are any number of genetic unknowns that impact underlying cancer biology.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles
ASBMB names 2025 fellows
American Society for Biochemistry and Molecular Biology honors 24 members for their service to the society and accomplishments in research, education, mentorship, diversity and inclusion and advocacy.
When Batman meets Poison Ivy
Jessica Desamero had learned to love science communication by the time she was challenged to explain the role of DNA secondary structure in halting cancer cell growth to an 8th-grade level audience.
The monopoly defined: Who holds the power of science communication?
“At the official competition, out of 12 presenters, only two were from R2 institutions, and the other 10 were from R1 institutions. And just two had distinguishable non-American accents.”
In memoriam: Donald A. Bryant
He was a professor emeritus at Penn State University who discovered how cyanobacteria adapt to far-red light and was a member of the American Society for Biochemistry and Molecular Biology for over 35 years.
Yes, I have an accent — just like you
When the author, a native Polish speaker, presented her science as a grad student, she had to wrap her tongue around the English term “fluorescence cross-correlation microscopy.”
Professorships for Booker; scholarship for Entzminger
Squire Booker has been appointed to two honorary professorships at Penn State University. Inayah Entzminger received a a BestColleges scholarship to support their sixth year in the biochemistry Ph.D. program at CUNY.